Company: STAA
Filing Date: 2025-10-21
Form Type: PX14A6G
Source: 0001193125-25-244217
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-21
Form: PX14A6G
Chunk 1
---
 as follows:

October 21, 2025

STAAR Surgical Company

25510 Commercentre Drive

Lake Forest, CA 92630

Dear Members of the Board:

We are writing to express concern over recent representations by the Company regarding the proposed merger with Alcon, to urge you to hold the special meeting
of shareholders on October 23, 2025, as planned, and to reiterate our confidence in the future of the Company after the shareholder vote on the proposed merger is concluded and presumably defeated. We continue to oppose the proposed merger and have accordingly voted our shares against it.

1. Recent Company Disclosures Are Disingenuous

To start with, we are troubled by recent characterizations from the Company regarding the proposed merger. STAAR’s October 16 press release
disingenuously touts that “Despite Broadwood’s assertions, STAAR has not received any proposal to acquire the Company other than from Alcon.”

To be clear, shareholders such as Broadwood and us have not alleged that STAAR has received “proposals” or “offers” to acquire the
Company other than from Alcon. Instead, shareholders have asserted that the Company ran a deficient process leading up to the proposed merger. We have criticized the Board for having chosen to meaningfully engage only with Alcon rather than properly
conducting a market check or soliciting interest from additional counterparties to maximize value for shareholders. Our view is that a real process, and one perhaps conducted at a more appropriate time from the standpoint of the Company’s best
interests, may have led to credible proposals.

We also take issue with STAAR’s recent press release of October 16 touting that “Alcon is
paying STAAR stockholders a 59% premium to STAAR’s 90-day Volume Weighted Average Price (VWAP).”

1

We struggle to understand how the Company can genuinely view that stated premium as compelling for
shareholders, given that business cycles clearly impacting the Company last substantially more than 90 days. In recent earnings disclosures, the Company has consistently acknowledged working through cyclical challenges, such as excess inventory and
macroeconomic trends in China. It was never the Company’s expectation, prior to the merger announcement, that these challenges and other headwinds would be resolved within one or two quarters. While a 59% premium may appear compelling when
viewed in isolation, shareholders understand that this figure is being presented without the fuller context of the Company’s long-term trajectory – context the